New framework prioritizes semaglutide and tirzepatide across most obesity-related conditions
The European Association for the Study of Obesity (EASO) has released new guidance positioning the incretin mimetics semaglutide and tirzepatide as…
EASO Recommends GLP-1 Agonists as First-Line Treatment for Obesity and Complications
